$0.6350
-0.0083-1.29%
Últ. Act.: Oct 20, 8:40 AM
$0.6350
-0.0083-1.29%
Standard BioTools (LAB) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Standard BioTools (LAB) publicó su última previsión de mayo 5, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $80M - $85M para el período.
En comparación con la previsión anterior, Standard BioTools mantenido redujo su previsión de ingresos desde un rango anterior de $80M - $85M.
Standard BioTools ha emitido 21 actualizaciones de orientación entre el enero 9, 2023 y el mayo 5, 2026. During this period, the company raised its outlook 5 times and lowered it 6 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.03 | $-0.02 | $-0.04 | $-0.04 |
| Actual | $-0.07 | $-0.04 | $0.05 | $-0.09 |
| Surprise | -133.3% | -100.0% | +225.0% | -125.0% |
| Revenue | ||||
| Estimate | $20.9M | $17.8M | $18.5M | $18.0M |
| Actual | $20.1M | $21.1M | $23.8M | $19.6M |
| Surprise | -3.90% | +19.1% | +28.6% | +8.62% |
| Metric | Q3 '26E | Q4 '26E |
|---|---|---|
| Earnings Per Share (Non-GAAP) | ||
| Consensus | $-0.02 | $-0.02 |
| Revenue | ||
| Consensus | $18.8M | $21.0M |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $-0.07 | $-0.03 | -133.3 % |
| Q1 | May 5, 2026 | $-0.04 | $-0.02 | -100.0 % |
| Q4 | Feb 24, 2026 | $0.05 | $-0.04 | 225.0 % |
| Q3 | Nov 4, 2025 | $-0.09 | $-0.04 | -125.0 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $20.10M | $20.92M | -3.90 % |
| Q1 | May 5, 2026 | $21.15M | $17.75M | 19.1 % |
| Q4 | Feb 24, 2026 | $23.80M | $18.50M | 28.6 % |
| Q3 | Nov 4, 2025 | $19.55M | $18.00M | 8.62 % |